Posted by Michael Wonder on 20 Apr 2019
Health Canada approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis
18 April 2019 - Approval of Skyrizi (risankizumab) is based on results from clinical studies showing significant improvement in levels of skin clearance after just 16 weeks and at 52 weeks with every 3 month dosing in more than 2,000 adult patients.
AbbVie announced today that Health Canada has approved Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Skyrizi received Health Canada approval based on results from four pivotal Phase 3 studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluating more than 2,000 patients with moderate to severe plaque psoriasis.
Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally.
